Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma

Lionel Perrier, Anne Lefranc, Philippe Quittet, Philippe Moreau, Carole Siani, Hervé Ghesquières (), Fabrice Jardin, Bertrand Favier, Norbert Ifrah, Séverine Lissandre, David Pérol () and Catherine Sebban
Additional contact information
Anne Lefranc: Centre Léon Bérard [Lyon]
Philippe Quittet: Service d'hématologie et oncologie médicale - Hôpital Lapeyronie [CHU Montpellier] - CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier] - UM1 - Université Montpellier 1 - CHRU Montpellier - Centre Hospitalier Régional Universitaire [Montpellier] - UM - Université de Montpellier
Philippe Moreau: Hématologie et oncologie pédiatrique
Hervé Ghesquières: FNCLCC - Département Hématologie - Centre Léon Bérard [Lyon]
Fabrice Jardin: IADI - Imagerie Adaptative Diagnostique et Interventionnelle - INSERM - Institut National de la Santé et de la Recherche Médicale - UL - Université de Lorraine
Bertrand Favier: Department of Pharmacy - Centre Léon Bérard [Lyon]
Norbert Ifrah: Service d'hématologie clinique [Avicenne] - UP13 - Université Paris 13 - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP) - Hôpital Avicenne [AP-HP] - AP-HP - Assistance publique - Hôpitaux de Paris (AP-HP)
Séverine Lissandre: Service d'hématologie [Tours] - CHRU Tours - Centre Hospitalier Régional Universitaire de Tours - Hôpital Bretonneau
David Pérol: Department of Biostatistics - Centre Léon Bérard [Lyon]
Catherine Sebban: Department of Medical Oncology - Centre Léon Bérard [Lyon]

Post-Print from HAL

Keywords: Cost-effectiveness; Pegfilgrastim; Filgrastim (search for similar items in EconPapers)
Date: 2013
References: Add references at CitEc
Citations:

Published in Applied Health Economics and Health Policy, 2013, 11 (2), pp. 129-138. ⟨10.1007/s40258-013-0011-7⟩

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
Journal Article: Cost Effectiveness of Pegfilgrastim Versus Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Lymphoma and Myeloma (2013)
Working Paper: Cost-effectiveness of Pegfilgrastim versus Filgrastim after high-dose chemotherapy and autologous stem cell transplantation in patients with lymphoma and myeloma (2011)
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:hal:journl:halshs-00752571

DOI: 10.1007/s40258-013-0011-7

Access Statistics for this paper

More papers in Post-Print from HAL
Bibliographic data for series maintained by CCSD ().